Interchange Capital Partners LLC Sells 539 Shares of Sanofi (NASDAQ:SNY)

Interchange Capital Partners LLC lessened its holdings in shares of Sanofi (NASDAQ:SNY) by 8.9% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 5,548 shares of the company’s stock after selling 539 shares during the period. Interchange Capital Partners LLC’s holdings in Sanofi were worth $268,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in SNY. Synergy Asset Management LLC acquired a new position in Sanofi during the 4th quarter worth $25,000. McClarren Financial Advisors Inc. raised its position in shares of Sanofi by 952.6% during the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock worth $28,000 after acquiring an additional 543 shares during the last quarter. Lee Danner & Bass Inc. acquired a new position in shares of Sanofi during the fourth quarter valued at $31,000. Sunbelt Securities Inc. boosted its holdings in Sanofi by 72.1% in the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after acquiring an additional 313 shares during the last quarter. Finally, Sierra Ocean LLC acquired a new stake in Sanofi in the fourth quarter worth about $44,000. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

SNY has been the topic of a number of research reports. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. The Goldman Sachs Group initiated coverage on shares of Sanofi in a report on Friday. They issued a “neutral” rating and a $65.00 price objective on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Finally, Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Three equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Sanofi presently has a consensus rating of “Moderate Buy” and an average target price of $62.50.

Sanofi Stock Down 1.7 %

Shares of NASDAQ SNY opened at $55.93 on Tuesday. Sanofi has a 52-week low of $45.22 and a 52-week high of $60.12. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The stock has a market cap of $141.94 billion, a P/E ratio of 22.46, a P/E/G ratio of 1.01 and a beta of 0.58. The firm has a 50 day moving average price of $54.70 and a 200 day moving average price of $52.84.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Analysts expect that Sanofi will post 4.36 EPS for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.